Neovascular age-related macular degeneration（nAMD） is an ocular disease causing blind，characterized by choroidal neovascularization（CNV）. Anti-vascular endothelial growth factor（VEGF） therapy has become the first-line treatment of nAMD and gains good therapeutic effects on improving and maintaining eyesight. At present，the frequency of anti-VEGF therapy is not unanimous，but main therapeutic strategies at home and abroad contain monthly and bimonthly fixed treatment，PRN regimen，treat and extend（T & E） regimen. In recent years，studies have found that T & E regimen shows the superiority in guaranteeing visual benefits and reducing injections，which is recommended by experts recently. However，the therapeutic effect and frequency still need to be studied. This review summarized the recent updates on T & E regimen among various anti-VEGF agents for the treatment of nAMD，hoping to supply a reference for clinical treatment.